Saxenda for weight loss: what the GLP-1 science actually shows

What did @dr.santiagomesa actually say?

The caption does the heavy lifting here. @dr.santiagomesa describes Saxenda (liraglutide) as a GLP-1 receptor agonist that works at the brain level, suppressing appetite and extending satiety. The framing is measured: it's positioned as "a useful tool within a medical treatment" for overweight or obesity, not a standalone cure. The actual spoken transcript, unfortunately, is largely incoherent and appears to be a transcription artifact rather than real speech. That means the substantive medical content lives entirely in the caption.

What the caption gets right in framing: it does not promise dramatic results, does not suggest Saxenda replaces lifestyle changes, and does include the phrase "medical treatment," implying supervision. That kind of hedging matters in a space flooded with people selling weight loss as a weekend project. Still, the caption cuts off mid-sentence, so we're fact-checking an incomplete claim.

Does the science back this up?

Yes, the core pharmacology described is accurate. Liraglutide does act as a GLP-1 receptor agonist, and it does suppress appetite partly through central nervous system mechanisms, not just gut signaling. The clinical data are real and reasonably strong.

The landmark SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) found that patients on 3 mg liraglutide daily lost an average of 8.4 kg over 56 weeks compared to 2.8 kg on placebo. About 63% of liraglutide patients lost at least 5% of body weight. That is a clinically meaningful result, though it is worth noting the trial was industry-funded by Novo Nordisk, the manufacturer. Separately, Iepsen et al. (2015, European Journal of Endocrinology) confirmed that liraglutide reduces hunger scores and increases satiety through both peripheral and central GLP-1 receptor activation. The brain-level appetite suppression claim the creator makes is supported by this mechanistic research.

What did they get wrong (or right)?

On the science, the creator gets it right. The caption's description of liraglutide's mechanism is accurate and does not overstate the drug's effects. Credit where it's due.

What is missing, though, matters. The caption does not mention the discontinuation problem: in the SCALE trial, a significant proportion of patients regained weight after stopping liraglutide. A 2022 follow-up analysis (Wadden et al., Obesity) showed that weight regain after stopping GLP-1 agonists is the norm, not the exception. There is also no mention of the side effect profile. Nausea affects roughly 40% of patients in the first weeks of treatment (Pi-Sunyer et al., 2015), and gastrointestinal events are the most common reason for discontinuation. Pancreatitis risk, though rare, is listed in the prescribing information. Thyroid C-cell tumor risk observed in rodent studies is also in the FDA label, though human relevance remains debated.

• The mechanism claim: accurate
• The "useful tool" framing: accurate and appropriately cautious
• Missing: weight regain after discontinuation
• Missing: common side effects including nausea and GI distress
• Missing: the fact that liraglutide has largely been superseded by semaglutide in clinical practice

What should you actually know?

Saxenda works, but it is not the strongest option anymore. That is the honest clinical reality the caption skips over.

Semaglutide (Wegovy, 2.4 mg weekly) has shown roughly double the weight loss efficacy in head-to-head comparisons. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed 14.9% mean body weight reduction with semaglutide versus roughly 5-8% with liraglutide in the SCALE data. Tirzepatide (Zepbound) shows even larger effects in the SURMOUNT trials. Liraglutide is still FDA-approved for weight management and is appropriate for certain patients, but a TikTok in 2024 that does not acknowledge where liraglutide sits in the current treatment hierarchy is giving an incomplete picture.

The more important point: none of these medications are permanent weight management solutions on their own. They require lifestyle support, and most patients need to stay on them long-term to maintain results. Anyone considering Saxenda should have this conversation with a licensed provider, not a TikTok caption.

Bottom line

The science in this post is accurate as far as it goes. The mechanism is correctly described, the framing is appropriately medical, and the creator does not make wild efficacy promises. But the post is incomplete in ways that matter to real patients making real decisions. Weight regain after stopping, the side effect burden, and the availability of more effective agents in the same drug class all deserved a mention. A 39,000-view post on weight loss medication carries real-world consequences, and "a useful tool" without context leaves too much on the table.